Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo Nordisk, Hims & Hers Health Shares React to Lawsuit
Published: February 09, 2026 by: Schaeffers Research
Sentiment: Negative
Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49.
Read More
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug market
Published: February 09, 2026 by: WSJ
Sentiment: Neutral
The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.
Read More
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn
Published: February 09, 2026 by: Investopedia
Sentiment: Neutral
Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.
Read More
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
Published: February 09, 2026 by: CNBC
Sentiment: Negative
The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients. In a letter to Novo dated Feb. 5, the FDA requested that the drugmaker take immediate action to address the violations, which could include ceasing all ads containing misleading claims.
Read More
HIMS Slides 25% After NVO Sues Company Over Generic GLP-1 Pills
Published: February 09, 2026 by: Schwab Network
Sentiment: Negative
Legal issues hits Hims & Hers (HIMS). Novo Nordisk (NVO) filed a lawsuit against the company over allegedly selling unapproved Wegovy and Ozempic weight loss drugs.
Read More
FDA says Novo's obesity pill TV Ad is false or misleading
Published: February 09, 2026 by: Reuters
Sentiment: Negative
The Food and Drug Administration said a television advertisement for Novo Nordisk's weight loss pill is "false or misleading", according to a letter dated February 5.
Read More
Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.
Read More
Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reason
Published: February 09, 2026 by: CNBC Television
Sentiment: Neutral
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the fight between Novo Nordisk and Hims & Hers over GLP-1 drugs, immunization policies in the U.S., and more.
Read More
Novo Nordisk: The Selloff Is A Blessing In Disguise
Published: February 06, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S remains a Strong Buy despite a sharp 2026 outlook-driven selloff, with current pricing reflecting excessive market pessimism. NVO faces near-term headwinds from U.S. pricing pressure, patent expirations, and manufacturing ramp-up delays, but underlying free cash flow and profitability remain robust. The Wegovy pill's rapid uptake and first-mover advantage, alongside CagriSema's promising efficacy, position NVO for long-term GLP-1 market leadership.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 5 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Read More
LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic
Published: February 05, 2026 by: Schwab Network
Sentiment: Positive
After Eli Lilly (LLY) posted earnings that outshined Novo Nordisk's (NVO) decelerating growth, Scott Zari feels comfortable calling Eli Lilly the dominant winner in the weight loss drug race. While he notes Novo Nordisk's pill as "important" to consumers, it's Eli Lilly's injectable he sees continuing to lead GLP-1 momentum.
Read More
Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding' Over Cheaper Wegovy Version
Published: February 05, 2026 by: WSJ
Sentiment: Negative
Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan.
Read More
Novo Nordisk CEO: Hims' $49 compounded Wegovy pill a 'waste' of money
Published: February 05, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers Health was launching a cut-price version of Novo's blockbuster Wegovy weight loss pill.
Read More
Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
Published: February 05, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an introductory price of $49 per month.
Read More
Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk's shares
Published: February 05, 2026 by: Market Watch
Sentiment: Positive
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Read More
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Published: February 05, 2026 by: CNBC
Sentiment: Negative
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock dropped on the news, while Hims shares jumped.
Read More
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
Published: February 05, 2026 by: MarketBeat
Sentiment: Neutral
The first week of February 2026 will be remembered as the day the pharmaceutical sector's most famous partnership officially dissolved. For years, Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO traded in lockstep, their stock charts nearly identical as they raced to supply the world with weight-loss medicines.
Read More
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
Published: February 04, 2026 by: CNBC
Sentiment: Positive
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ahead thanks to its blockbuster medicines.
Read More
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Positive
Eli Lilly and Company defies valuation skeptics, posting 45% revenue growth and 96% EPS growth in 2025, with 2026 guidance projecting $80–83 billion in revenue and $33.5–35 EPS. LLY's manufacturing investments and pipeline strength, especially tirzepatide and retatrutide, position it to outpace Novo Nordisk A/S in the GLP-1/obesity market. NVO faces 2026 revenue and profit declines due to U.S. pricing pressures, patent expiries, and manufacturing disadvantages despite a strong dividend yield.
Read More
In Weight Loss Drug Battle For 2026, Eli Lilly Pulls Ahead Of Novo Nordisk
Published: February 04, 2026 by: Benzinga
Sentiment: Positive
Over the last two days, Novo Nordisk A/S (NYSE: NVO) stock has plunged around 18% after the company issued a softer outlook for fiscal 2026.
Read More
Novo Nordisk Q4: Slumping Due To Weak Guidance
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S shares dropped ~20% after issuing weaker-than-expected 2026 guidance despite strong 2025 obesity drug growth. NVO's 2025 revenue rose 10% at constant currency rates, but margin compression and higher costs left net profit flat; the obesity franchise grew 31%. 2026 guidance forecasts ~9% constant currency revenue and profit decline, driven by U.S. drug pricing pressures and patent expirations.
Read More
Novo to launch Ozempic pill for diabetes in second quarter of this year
Published: February 04, 2026 by: Reuters
Sentiment: Positive
Novo Nordisk said on Wednesday it will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year.
Read More
Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade)
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S faces disappointing 2026 guidance, projecting a 5–13% revenue and operating profit decline despite Wegovy pill adoption. Margin pressure arises as the oral Wegovy pill is costlier to produce and priced lower than injectables, compressing profitability even amid surging demand. US pricing pressure, currency headwinds, and competition from Eli Lilly compound risks, pushing NVO's FWD price/FCF multiple to 33x amid deteriorating fundamentals.
Read More
Novo Nordisk Stock Sinks on Weak Sales Forecast
Published: February 04, 2026 by: Schaeffers Research
Sentiment: Negative
Novo Nordisk A/S (NYSE:NVO) stock is extending last session's 14.6% slide, down 3.7% to trade at $48.44 at last glance.
Read More
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
Read More
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
Read More
Novo Nordisk risks weight-loss price war as discount pressures deepen
Published: February 04, 2026 by: Reuters
Sentiment: Negative
Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "unprecedented" price pressure forces it to slash the cost of its blockbuster Wegovy drug in the United States, analysts and investors said.
Read More
Novo Nordisk CEO on 2026 Forecast and GLP-1 Pricing
Published: February 03, 2026 by: Bloomberg Markets and Finance
Sentiment: Neutral
Novo Nordisk CEO Mike Doustdar discusses the company's updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk's oral GLP-1 treatment Wegovy, which has reached over 170,000 patients within four weeks of launch.
Read More
Novo Nordisk's stock tumbles as drugmaker lays out case for declining sales in 2026
Published: February 03, 2026 by: Market Watch
Sentiment: Negative
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406